Research Article |
Corresponding author: Aty Widyawaruyanti ( aty-w@ff.unair.ac.id ) Academic editor: Magdalena Kondeva-Burdina
© 2024 Suryanto Suryanto, Lidya Tumewu, Hilkatul Ilmi, Achmad Fuad Hafid, Suciati Suciati, Aty Widyawaruyanti.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation:
Suryanto S, Tumewu L, Ilmi H, Hafid AF, Suciati S, Widyawaruyanti A (2024) Antimalarial activity of Cratoxyarborenone E, a prenylated xanthone, isolated from the leaves of Cratoxylum glaucum Korth. Pharmacia 71: 1-7. https://doi.org/10.3897/pharmacia.71.e126316
|
This research aims to discover active compounds from the leaf extract from Cratoxylum glaucum using the bioassay-guided isolation method. The multistage extraction of C. glaucum leaves was conducted using n-hexane, dichloromethane, and methanol. The LDH assay was employed to analyze antimalarial activity, and the Resazurin assay was used to measure cytotoxicity values. The structure of the active isolates was determined using spectroscopic techniques. The compound 1 was successfully isolated from the dichloromethane extract of C. glaucum leaves (Cg.FD) and confirmed as a prenylated xanthone namely cratoxyarborenone E. The in vitro antimalarial activity showed an IC50 value of 5.82 ± 0.04 μM, the cytotoxicity assay exhibited a CC50 value of 20.74 ± 0.04 µM, and the SI value was determined to be 3.56. Our research demonstrates that cratoxyarborenone E was first reported from Cg.FD and shows promise as a prospective candidate for new antimalarial drugs.
antimalarial, Cratoxylum glaucum, prenylated xanthone, LDH assay, Plasmodium falciparum
Malaria, a disease caused by parasites of the Plasmodium species, is spread to humans through the sting of an infected female Anopheles mosquito (
Drug resistance and side effect reports are two challenges in treating malaria. Resistance against antimalarial medications obstructs control endeavors and heightens the susceptibility to sickness and death resulting from malaria (
According to reports, the Cratoxylum genus could be investigated as a viable plant candidate for discovering novel antimalarial compounds. Major categories of polyphenolic compounds with antimalarial action have been identified in Cratoxylum, including xanthone, flavonoids, quinones, anthraquinones, and phenols (
Therefore, based on the chemotaxonomy approach, Cratoxylum glaucum Korth holds promise as a candidate for discovering antimalarial compounds. This plant is traditionally known as gerunggang merah. Nearly every part of the plant, especially the leaves, is used as a traditional medicine to promote breast milk production and treat fever, cough, and diarrhea (Yingngam et al. 2014;
Studies regarding the antimalarial properties of this plant have yet to be reported. Considering the potential content of its compounds, research regarding the efficacy of this plant as a potential antimalarial can be carried out.
The present study aims to investigate the antimalarial properties of the C. glaucum leaf extract, which has the potential for further research in searching for possible antimalarial compounds. In this context, bioassay-guided isolation will isolate active compounds that inhibited P. falciparum growth on a lactate dehydrogenase (LDH) assay.
The fresh leaves of C. glaucum were obtained from the Balikpapan Botanical Garden, East Kalimantan, Indonesia. Dr. Ratih Damayanti, S.Hut. M. Si., Directorate of Scientific Collection Management at BRIN Cibinong, Jakarta, Indonesia, determined the plants for identification and authentication. A voucher specimen has been issued (B-847/II.6.2/IR.01.02/5/2023) by the Directorate of Scientific Collection Management at BRIN Cibinong, Jakarta, Indonesia.
The leaves of C. glaucum (Cg.F) were subjected to a multistage extraction process. Initially, a powder of Cg.F (1 kg) was extracted with solvents in order of polarity, such as n-hexane (4.5 L), dichloromethane (3 L), and methanol (3 L). The solvents were subsequently removed from each extract under pressure to yield n-hexane extract (Cg.FH, 22.56 g, 2.26% w/w), dichloromethane extract (Cg.FD, 46.82 g, 4.68% w/w), and methanol extract (Cg.FM, 46 g, 4.6% w/w). After the initial antimalarial screening and determining the IC50 value, Cg.FD exhibited the strongest activity and chose to separate further. The extract (Cg.FD, 2.5 g) was fractionated under vacuum liquid chromatography (VLC) with hexane-EtOAc gradient elution (100:0–0:100) and produced 12 fractions (Cg.FD-F1–F12). Only 5 fractions (Cg.FD-F3; F4; F5; F6; and F8) showed more than 50% inhibition on antimalarial screening. Subsequently, the IC50 value of the active fraction is determined; Cg.FD-F5 showed the strongest activity and was carried out to the next separation. The fraction (Cg.FD-F5, 1.042 mg) was separated using Sephadex LH-20 with a chloroform-methanol isocratic elution (2:8 v/v) and obtained into nine fractions (Cg.FD-F5.1–F5.9). Fraction Cg.FD-F5.5 was identified as compound 1 (102 mg).
The structure of compound 1 was checked for purity level using HPLC reverse phase column C-18 with methanol-water isocratic elution (8.5:1.5 v/v) with a flow rate of 1.5 mL/min and characterized using a UV absorbance detector in HPLC (Shimadzu, Kyoto, Japan). Mass spectra were utilized with the UPLC-Q-TOF-MS system (Shimadzu, Kyoto, Japan). NMR spectroscopy methods (JEOL 400 MHz and 100 MHz), including 1D NMR (1H-NMR and 13C-NMR) and 2D NMR (HMBC) techniques. The obtained spectral data were compared with previously reported studies.
The Plasmodium falciparum chloroquine-sensitive (3D7 strain) was obtained from the Center for Natural Product Medicine and Research Development (NPMRD), the Institute of Tropical Disease (ITD), Universitas Airlangga, Indonesia. The O type red blood cells (RBC) was acquired from the Indonesian Red Cross of Surabaya, Indonesia. The parasites of P. falciparum were grown using red blood cells (type O) at a hematocrit of 2% with RPMI-1640 media (Gibco, Waltham, USA), albumax 10% (v/v), and 50 μg/mL hypoxanthine (Sigma) under 5% O2, 5% CO2, and 90% NO2 at a temperature of 37 °C.
Extracts, fractions, and compound 1 of C. glaucum were determined for their antimalarial activity. The culture of parasites was synchronized using sorbitol 5% w/v to obtain the ring stage. The sample with a variant concentration of 0.01, 0.05, 0.1, 0.5, 1, 5, 10, and 50 μg/mL was put into each well plate in one microliter and replicated three times. Ninety-nine microliters of parasite (ring-stage) were added. Subsequently, it was incubated for 72 hours at 37 °C in a mixture of gases (5% O2, 5% CO2, and 90% NO2). After that, the well plate was stored at -30 °C overnight. The original LDH-buffer solution, which contained 10 mL of Tris-HCl, Triton X-100, sodium L-lactate, and deionized water, was enhanced with APAD stock solution (10 mg/mL, Oriental Yeast Co., Ltd.), 2 mg of NBT (10 mg/mL, Sigma), and 200 µL of diaphorase stock solution (50 units/mL, Sigma). Then, carefully mix the ingredients of the LDH buffer solution and store it in the absence of light. Subsequently, 90 µL of the prepared substrate was put into each well plate. This well plate was covered with aluminum foil, placed in a flatbed shaker set at 650 rpm, and maintained at room temperature. Afterward, the plate was subjected to incubation for 30 minutes. The absorbance of each well was measured using the multiscan sky-high microplate spectrophotometer (Thermo Fisher Scientific) at a wavelength of 650 nm (
The cytotoxicity assay of compound 1 was investigated using the resazurin assay. Vero cell lines were cultured in high glucose (D-MEM) media supplemented with L-Glutamine, Phenol Red (Wako, Fujifilm), NaHCO3, fetal bovine serum 10% (v/v) (Gibco), and Penicillium streptomycin 1% (v/v) (Sigma). One hundred microliters cultured (1×106) were seeded into a micro-96 well plate and incubated for 24 hours at a temperature of 37 °C. Then, discarded the medium and added serial dilutions of compound 1 with the following series of concentrations: 100, 50, 25, 12.5, and 6.25 µg/mL. Then, the well plate was subsequently incubated for 2 days in a CO2 5% incubator at 37 °C. After incubation, a well plate was filled with 10 µL of resazurin solution (0.5 mM) and incubated for 4 hours. After the incubation, fluorescence measurements were performed using a Nivo plate reader (PerkinElmer) at a wavelength for excitation of 530 nm and a wavelength for emission of 595 nm (
The average of three repeat experiments ± standard deviation shows all the data. The antimalarial activity (IC50) and cytotoxicity (CC50) values were calculated using GraphPad Prism 9.3.0 edition for Windows (GraphPad Software Inc., USA). The selectivity index (SI) is determined by dividing the CC50 value by the IC50 value.
Currently, drug discovery for new antimalarials is highly necessary because of the increasing drug resistance in malaria and the expanding cases of malaria. Medicinal plants are known to have great potential due to their secondary metabolite content for discovering a new drug candidate, particularly for malaria. Bioassay-guided isolation is now widely used to sift through extensive collections of plant extracts and fractions to obtain the active compounds. These assays isolate bioactive compounds from intricate mixtures, utilizing separation and analytical methods. The process entails sequentially testing fractionated material for its activity in a bioassay and assessing its purity through analytical techniques (
The antimalarial activity of three extracts of C. glaucum leaves (Cg.FH, Cg.FD, and Cg.FH) has been evaluated. The dichloromethane extract (Cg.FD) has the strongest activity inhibiting P. falciparum, as shown by an IC50 value of 2.12 ± 0.04 μg/mL (Table
Sample | IC50 (µg/mL) |
---|---|
Cg.FH | 6.10 ± 0.02 |
Cg.FD | 2.12 ± 0.04 |
Cg.FM | 4.51 ± 0.03 |
Fractionation on Cg.FD resulted in five active fractions (F3; F4; F5; F6; and F8), and the fraction Cg.FD-F5 exhibited the strongest activity with an IC50 value of 1.5 ± 2.91 μg/mL (Table
Compound (1): Yellow crystal, UV absorbance 240, 262, 318, 378 nm. m/z 410.1801 [M+H]+ (calcd for C24H26O6, 410.1808). 1H NMR (400 MHz, acetone-d6): 6.29 (s, 1H, H-2, ArH), 7.50 (s, 1H, H-8, ArH), 5.25 (q, J 6.8 Hz, 1H, H-2’), 3.48 (d, J 6.8 Hz, 2H, H-1’), 1.63–1.76 (s, 3H, H-4’ and H-5’), 3.64 (d, 2H, J 6.8 Hz, H-1”), 5.31 (q, J 6.8 Hz, 1H, H-2”), 1.67–1.80 (s, 3H, H-4” and H-5”), 12.98 (1H, s, OH-1), 3.96 (3H, s, -OCH3-6). 13C NMR (100 MHz, acetone-d6): δC 161.34 (C-1), 97.43 (C-2), 162.42 (C-3), 106.41 (C-4), 124.24 (C-5), 152.54 (C-6), 147.43 (C-7), 107.56 (C-8), 180.37 (C-9), 155.30 (C-4a), 148.95 (C-5a), 116.32 (C-8a), 102.49 (C-9a), 21.45 (C-1’), 122.18 (C-2’), 131.09 (C-3’), 25.04 (C-4’), 17.18 (C-5’), 22.97 (C-1”), 122.92 (C-2”), 132.00 (C-3”), 25.04 (C-4”), 17.27 (C-5”), and 60.38 (C-OCH3-6). HMBC H-2/ C-1, C-4, C-9a; H-8/ C-6, C-8a, C-9; H-1’/C-3, C-4, C-4a, C-2’, C-8’; H-5’/C-4’; H-1”/C-5, C-6, C-3”, C-5”; H-2”/C4”, C5”; H-4”/C-3”, C-5”; H-5”/C-2”; OH-1/C-1, C-2, C-9a. Purity level on HPLC 254 nm: 98.301%; 210 nm: 97.785%; 365 nm: 98.658% (Suppl. material
The 1H-NMR and 13C-NMR spectra on compound 1 indicated a prenylated xanthone group, including the xanthone skeleton, hydroxyl, and two prenyl groups (Suppl. material
The HMBC of 2D NMR was used to confirm the locations of the two side chains in the isolated compound. The first prenyl protons at δH 3.48 (2H, d, H-1’) were assigned two bond correlations to δC 106.41 (C-4), three bond correlations to 162.42 (C-3), and 155.30 (C-4a). The second prenyl proton in δH 3.64 (2H, d, H-1”) was positioned at δC 124.24 (C-5) through two bond correlations and three bonds at 152.54 (C-6) (Suppl. material
Compound 1 has antimalarial activity with IC50 values of 2.13 ± 0.04 µg/mL (5.82 µM) and is categorized as having good antimalarial activity because it has an IC50 between 1 and 20 µM (
Cratoxyarborenone E was first reported in the extract of C. glaucum leaf extract. Based on the IC50 value, it showed good antimalarial activity and was relatively non-toxic at the CC50 value. This compound has the potential to be used as a new antimalarial drug.
This research was funded by the Education Funding Institution (LPDP) and the Education Funding Serving Center (BPPT), grant number: 00634/J5.2.3./BPI.06/9/2022; and Airlangga Research Funding through Penelitian Unggulan Airlangga (PUA), grant number: 297/UN3.15/PT/2023.
This research does not involve using any human subjects or animals.
Suryanto Suryanto: Phytochemistry and bioassay work, data analysis, and writing the original manuscript. Lidya Tumewu: Compound identification, review, and editing. Hilkatul Ilmi: Bioassay work, data analysis, review, and editing. Suciati Suciati: Compound identification and review. Achmad Fuad Hafid: Conceptualization, methodology, and review. Aty Widyawaruyanti: Conceptualization, methodology, and review.
The authors thank the Center of Natural Product Medicine Research and Development (NPMRD), and the Institute of Tropical Disease (ITD), Universitas Airlangga, for granting access to the research facilities.
Supplementary data
Data type: pdf
Explanation note: fig. S1: 1H-NMR of compound 1 (cratoxyarborenone E); fig. S2: 13C-NMR of compound 1 (cratoxyarborenone E); fig. S3: HMBC of compound 1 (cratoxyarborenone E); fig. S4: UV absorbance of compound 1 (cratoxyarborenone E); fig. S5: Mass spectrometry of compound 1 (cratoxyarborenone E); fig. S6. Purity level of compound 1 (cratoxyarborenone E) on HPLC.